ASCO 2020 | ProPSMA: A Callout to the Nuclear Medicine Community

Michael Hofman • 20 May 2020

General Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617

Michael Hofman, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses what is needed to advance radiology imaging and therapy, including the use of theranostics in the treatment of prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

177Lu-PSMA-617 vs. cabazitaxel for mCRPC

Michael Hofman • 20 May 2020

ProPSMA: PSMA-PET/CT imaging for high risk prostate cancer

Michael Hofman • 18 Jul 2020

TheraP: LuPSMA versus cabazitaxel for prostate cancer

Michael Hofman • 16 Feb 2021

177Lu-PSMA-617 for the early treatment of prostate cancer

Michael Hofman • 16 Feb 2021

Related Videos

The challenge of validating new biomarkers

Hisham Mehanna • 29 Nov 2018

Considerations for the long-term effects of androgen deprivation therapy

Bertrand Tombal • 16 Nov 2018

Reactivating the host immune response against cancer: new genetic discoveries

Sergio Quezada • 26 Nov 2018

Digital pathology: improving the landscape of cancer diagnosis

Manuel Salto-Tellez • 26 Nov 2018